Francis D'Addario’s Post

Old and new collective knowledge spells cancer progress. New Solution for Metastatic Ovarian Cancer Based on Approach From Nearly a Century Ago https://lnkd.in/ehqPYj3N

Old and new collective knowledge spells cancer progress. New Solution for Metastatic Ovarian Cancer Based on Approach From Nearly a Century Ago https://lnkd.in/ehqPYj3N

https://lnkd.in/eeHznPTi Our new Review on IL-10 in ovarian cancer. Is it time for ICI+anti IL-10 agents to be studied clinically in ovarian cancer patients?

Castle Biosciences' TissueCypher® test can offer patients with Barrett's esophagus a clearer picture of their risk of developing esophageal cancer, which is the 8th most common form of cancer worldwide and the 6th leading cause of cancer death (due in part to late diagnoses). Learn more about how TissueCypher can help (via USA TODAY and Mediaplanet USA): https://lnkd.in/gMBycc73

Exciting advances are finally being made in the battle against small cell lung cancer (SCLC), as reported by MD Anderson Cancer Center. Dr. Carl Gay and his team have identified four subtypes of SCLC, paving the way for more personalized and effective treatments. Using blood-based assays to rapidly classify these subtypes means faster, more tailored therapies, moving us away from the one-size-fits-all approach. "We have a lot of new options that I think are going to be game changers in treating small cell lung cancer," said Dr. Gay. #lungcancer #sclc #medicalinnovation https://lnkd.in/g8Q-Dz46

The post sheds light on the crucial role of exosomes and microRNAs in the early detection of pancreatic cancer. Through the analysis of both free-floating and exosome-packaged microRNAs, significant advancements have been made in identifying this complex disease. A study involving over 100 individuals with pancreatic cancer showcased the test's exceptional accuracy in detecting both early and late stages of the illness. This milestone underscores the potential of exosomes and microRNAs as valuable tools for the prompt diagnosis of pancreatic cancer. Dive deeper into this groundbreaking research by visiting the provided link. #PancreaticCancer #EarlyDetection Link to the post: https://lnkd.in/e96whAzr

According to early clinical data, a new experimental blood test can detect stage 1 and 2 pancreatic cancer with 97% accuracy. Although pancreatic cancer accounts for just 3% of new cancer diagnoses, it's one of the most fatal due to the difficulty of detecting it at an early stage. A quicker and earlier diagnosis means it's much more likely the cancer can be surgically removed before it spreads to other parts of the body, significantly increasing the likelihood of a full recovery. The clinical trial included patients from the US and Asia and will now be studied on a larger scale. #liquidbiopsy #IVD #cancerdiagnostics

Castle Biosciences' TissueCypher® test can offer patients with Barrett's esophagus a clearer picture of their risk of developing esophageal cancer, which is the 8th most common form of cancer worldwide and the 6th leading cause of cancer death (due in part to late diagnoses). Learn more about how TissueCypher can help (via USA TODAY and Mediaplanet USA): https://lnkd.in/gMBycc73

Gathering Around Cancer Conference: Changing paradigms in first-line lung cancer @AdamJSchoenfeld #lungcancer #celltherapy #GatheringAroundCancer https://lnkd.in/eNYEJ8VM

Gathering Around Cancer Conference: Changing paradigms in first-line lung cancer @AdamJSchoenfeld #lungcancer #celltherapy #GatheringAroundCancer https://lnkd.in/eNYEJ8VM